Success Stories: Chinese Student Earns NIW Approval for Alzheimer’s Disease Biomarker and Lipidomics Research
On October 7th, 2025, we received another EB-2 NIW (National Interest Waiver) approval for a Student in the field of Biochemistry (Approval Notice).
General Field: Biochemistry
Position at the Time of Case Filing: Student
Country of Origin: China
State of Residence at the Time of Filing: New Jersey
Approval Notice Date: October 7th, 2025
Processing Time: 1 month, 22 days (Premium Processing Requested)
Case Summary:
We are pleased to share the NIW approval of a student from China. At the time of filing, the client was conducting research in the United States focused on developing advanced mass spectrometry (MS) and lipidomic techniques to uncover the biochemical basis of Alzheimer’s disease (AD). His studies aim to identify early-stage biomarkers and therapeutic targets to improve diagnosis and treatment. With a strong record of publications, citations, and research support from leading institutions, he was a highly qualified candidate for NIW approval.
Research with National Importance
The client’s research integrates MS-based lipidomics and bioinformatics to identify biochemical mechanisms underlying AD progression. His work has revealed lipid imbalances associated with neuronal dysfunction and insulin resistance, providing new insight into disease development and biomarker discovery.
As Alzheimer’s disease affects millions of Americans and contributes substantially to national healthcare costs, his research directly supports U.S. priorities in neurological disease prevention and public health innovation. His findings also align with initiatives of the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) to advance early detection and treatment of neurodegenerative disorders.
Academic Achievements and Recognition
The client holds a master’s degree in chemistry and has authored 6 peer-reviewed journal articles and 3 book chapters, including publications in Nature Communications, The EMBO Journal, and JCI Insight. His work has been cited nearly 400 times by independent researchers, with four papers ranking among the top 1–10% most cited in biochemistry for their publication years.
He has also contributed to federally funded projects supported by the NIH, the National Institute of Aging, and the National Institute of Diabetes and Digestive and Kidney Diseases, endorsements that underscore the national relevance of his work.
Expert Recognition
Independent experts commended the client’s contributions to biochemistry and neurodegenerative disease research.
One recommender noted:
“In sum, [client] is a respected neuroscience researcher who has enhanced mass spectrometry technology in biomedical and neuroscientific research to support the biotechnology industry and, resultantly, strengthen the national economy.”
This statement reflects both the originality and the clinical value of his research.
NIW Approval and Outlook
The I-140 NIW petition was filed on August 15, 2025, and approved on October 7, 2025, under premium processing. With NAILG’s guidance, the client successfully demonstrated the national significance of his lipidomics and Alzheimer’s research.
He now continues his work in the United States, applying advanced MS techniques and computational tools to develop biomarker-driven strategies for early Alzheimer’s detection. His ongoing research supports the nation’s broader efforts to improve public health, biomedical innovation, and disease prevention.